Navigation Links
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
Date:4/23/2008

e similar adverse effects.

Such effects may include: photosensitivity, pseudotumor cerebri, and

anti-anabolic action (which has led to increased BUN, azotemia,

acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis

has been reported with the use of TYGACIL

-- The safety and efficacy of TYGACIL in patients with hospital-acquired

pneumonia have not been established

-- In clinical trials, the most common treatment-emergent adverse events

in patients treated with TYGACIL were nausea (29.5%) and vomiting

(19.7%)

-- TYGACIL may cause fetal harm when administered to a pregnant woman

-- The safety and effectiveness of TYGACIL in patients below age 18 and

lactating women have not been established

-- Clostridium difficile-associated diarrhea (CDAD) has been reported with

use of nearly all antibacterial agents, including TYGACIL, and may

range in severity from mild diarrhea to fatal colitis

-- Concurrent use of antibacterial drugs with oral contraceptives may

render oral contraceptives less effective

-- The use of TYGACIL during tooth development may cause permanent

discoloration of the teeth. TYGACIL should not be used during tooth

development unless other drugs are not likely to be effective or are

contraindicated

-- Prothrombin time or other suitable anticoagulant test should be

monitored if TYGACIL is administered with warfarin

-- Monotherapy should be used with caution in patients with clinically

apparent intestinal perforation

-- In patients with severe hepatic impairment (Child Pugh C), the initial

dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours.

Patients should be treated with caution and monitored for treatment

response

-- The following drugs should not be administered simultaneously through

th
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Oclaro, Inc. (NASDAQ: OCLR ), ... today outlined its complete line of fiber laser solutions ... a leading provider of diodes for industrial fiber laser ... operations, technology expertise and packaging technology to consistently deliver ...
... What:   Investigators from Northwestern ... 510(k) regulatory pathway—through which more than 90% of medical ... study is the most comprehensive survey to date about ... Devices and Radiological Health (CDRH) is currently weighing regulatory ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... is available in French . ... 14 year old teens, including brain structure and function, personality, ... who will go on to develop binge drinking within the ... and other variables such as life events and a family ... drinking. Whether or not the child had had a ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2
... 80 Million Dogs in U.S. Households - One in ... TV news story on canine cancer by Fox,42 News, ... at http://www.kptm.com ),has generated emotional, heartfelt response and ... new treatments for dogs with cancer,as well as the ...
... of Rutgers University is one of 10 2008 Pew ... Pew Charitable Trusts. Launched in 1991, the Pew Latin ... trained Latin American scientists who show potential for stimulating ... as well as fostering collaboration between scientists in Latin ...
... Group,Inc. (Nasdaq: NYER ) announced that its ... Pharmacy Service Agreement with East Boston,Neighborhood Health Center ... period effective October 6, 2008. Under terms of ... each prescription dispensed in,exchange for providing comprehensive Clinical ...
... Costs for ... India, WEST BEND, Wis., Nov. 12 Anthem ... a new international medical,tourism pilot product that will allow ... designated facilities in India.,Beginning in January 2009, Anthem will ...
... - A novel protein marker has been found that ... regenerate injured liver tissue has the potential for cell-replacement ... of Pennsylvania School of Medicine led by Linda Greenbaum, ... Gastroenterology, have demonstrated that cells expressing the marker can ...
... or President should have an independent health examination to ensure ... today. , Lord David Owen, a trained doctor and ... people are affected by the decisions of people in high ... general public to ensure that their decision making is not ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Announces Pharmacy Service Agreement with East Boston Neighborhood Health Center 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 3Health News:Stem cells with potential to regenerate injured liver tissue identified by Penn researchers 2Health News:World leaders must be more open about their health 2
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... female urinary stress incontinence (SUI) with a ... (BioArc™ SP) or a transobturator (BioArc™ TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
Medicine Products: